Feline Cryptococcosis

Feline cryptococcosis is the most common systemic fungal infection in cats worldwide, caused by encapsulated yeast-like organisms belonging to the Cryptococcus neoformans–Cryptococcus gattii species complex [1]. The complex encompasses eight distinct genotypes and various subtypes with differing geographical distributions, pathogenicity profiles, and antifungal susceptibility patterns [1]. Cats acquire infection from the environment, typically through inhalation of fungal propagules, and the disease preferentially affects the upper respiratory tract, central nervous system (CNS), eyes, and skin [1][6]. While potentially life-threatening if untreated, the prognosis is considered favorable in the majority of cases when diagnosis is made early and prolonged antifungal therapy is maintained [1].

Causative Agent Cryptococcus neoformans and Cryptococcus gattii (collectively the C. neoformans–C. gattii species complex) are encapsulated, basidiomycetous yeasts [1][6]. C. neoformans (formerly var. neoformans and var. grubii) is distributed globally and is the predominant species in cats; C. gattii is more geographically restricted (tropical and subtropical zones, with notable hyperendemicity in parts of Australia and the Pacific Northwest) but causes a disproportionately severe disease in some regions [1][5].

Environmental Source and Exposure The primary ecological niche of C. neoformans is soil enriched with avian (especially pigeon) droppings, which provide a nitrogen-rich substrate that promotes yeast proliferation [1][6]. C. gattii is classically associated with certain eucalyptus and other tree species. Cats are exposed by inhalation of small desiccated yeast cells or basidiospores present in contaminated dust and soil [1][5]. Because spores are airborne, even exclusively indoor cats are susceptible [5].

Pathogenesis After inhalation, propagules deposit in the nasal turbinates and mucosa, establishing a primary nasal infection [1][2]. The polysaccharide capsule is the organism's principal virulence factor: it impairs phagocytosis, inhibits complement activation, and blunts T-cell–mediated immune responses [1]. From the nasal cavity, infection may spread locally to the nasopharynx, sinuses, and orbit, or extend intracranially via the cribriform plate or hematogenous/lymphatic dissemination to reach the CNS, eyes, skin, lungs, and other organs [1][4][5]. Males appear to be affected more frequently than females in some case series, possibly reflecting behavioral differences in outdoor exposure [3]. Immunocompromised states (e.g., FIV, FeLV co-infection, corticosteroid therapy) can predispose to infection or more severe disseminated disease, although many affected cats have no identifiable immunosuppression [1][6].

Cytology and Direct Microscopy Fine-needle aspiration of nasal exudate, subcutaneous nodules, or lymph nodes with India ink preparation or modified Wright-Giemsa staining reveals the pathognomonic large encapsulated yeasts (5–20 µm body diameter with a thick mucoid capsule). This is often the fastest and least invasive confirmatory method [1][5].

Cryptococcal Antigen Detection (CALAS / Lateral Flow Assay) Detection of the capsular glucuronoxylomannan antigen in serum, urine, or cerebrospinal fluid (CSF) using latex agglutination (CALAS) or lateral flow assay is highly sensitive and specific [1][5]. The antigen titre (titer) is also valuable for monitoring treatment response — a declining titer correlates with therapeutic success, while a rising or persistently high titer signals treatment failure or relapse [1].

Culture Cryptococcus spp. grow readily on standard fungal media (Sabouraud dextrose agar) within days to weeks. Culture remains the gold standard for species/genotype identification and antifungal susceptibility testing (MIC determination), which is particularly relevant given geographic variation in susceptibility [1][5].

Histopathology Biopsy specimens stained with PAS, Gomori methenamine silver (GMS), or mucicarmine (which highlights the capsule) confirm tissue invasion and permit assessment of the host inflammatory response [5].

Imaging

• ·Computed tomography (CT) or MRI of the skull and nasal cavity: delineates turbinate destruction, soft-tissue mass lesions, and bony lysis; essential before rhinoscopy [1][5]
• ·MRI of the brain: detects CNS granulomas ("cryptococcomas"), leptomeningeal enhancement, or hydrocephalus in neurological cases [1]
• ·Thoracic radiographs or CT: may show interstitial or nodular pulmonary infiltrates in cats with respiratory involvement [2][5]

Endoscopy Caudal rhinoscopy using a retroverted flexible endoscope or vigorous orthograde saline flushing can reveal nasopharyngeal mass lesions and obtain diagnostic samples [4].

Laboratory Findings (Hematology and Biochemistry) Routine laboratory changes are often mild and non-specific but may include:

• ·CBC: mild normocytic normochromic anemia (decreased HCT), leukocytosis with or without a left shift; occasionally lymphopenia in disseminated disease
• ·Serum biochemistry: hyperglobulinemia (elevated GLOB) reflecting chronic antigenic stimulation; hypoalbuminemia (low ALB) in severe or chronic cases; variable elevation of liver enzymes (ALT) if hepatic dissemination occurs; BUN and CREA may be elevated if renal involvement is present
• ·CSF analysis: in CNS cases, increased protein, pleocytosis (predominantly mononuclear), and visible encapsulated yeasts on India ink preparation
• ·Antigen titres from serum/CSF provide the most diagnostically actionable laboratory information [1]

Antifungal Pharmacotherapy Treatment must be prolonged — typically many months — and monitoring of antigen titers guides duration [1].

• ·Fluconazole (triazole antifungal): the most widely used first-line agent in cats owing to excellent CNS penetration, oral bioavailability, and relatively favorable tolerability. Typical dosage: 50 mg/cat PO q12–24h [1][5].
• ·Itraconazole: an alternative or adjunctive triazole; has good tissue distribution but less reliable CNS penetration than fluconazole. Compounded liquid formulations may improve bioavailability in cats [1].
• ·Amphotericin B (AmB): reserved for severe or refractory cases due to nephrotoxicity risk. Lipid-based formulations (liposomal AmB) have a more favorable safety profile. Often used in combination with fluconazole for initial induction in life-threatening disease [1][5].
• ·5-Flucytosine (5-FC): rarely used as sole therapy but may be combined with AmB or fluconazole; risk of bone marrow suppression [1].
• ·Voriconazole and posaconazole: second-generation triazoles that may be considered for refractory or C. gattii infections with reduced susceptibility, though clinical data in cats are limited [5].

Treatment Duration Antifungal therapy should be continued until clinical resolution AND a negative or very low, stable cryptococcal antigen titer is achieved — often requiring 6–12 months or longer [1]. Premature discontinuation is a common cause of relapse.

Surgical/Procedural Interventions

• ·Debulking of large nasal or subcutaneous cryptococcal masses may reduce antigen load and facilitate drug penetration [1][4].
• ·Ventriculoperitoneal shunting is occasionally performed for hydrocephalus secondary to CNS disease [1].

Supportive Care

• ·Nutritional support (assisted feeding if anorexic)
• ·Anti-emetics and liver protectants as needed
• ·Management of concurrent FIV/FeLV infection
• ·Avoidance of immunosuppressive drugs (corticosteroids) during treatment wherever possible [1]

Monitoring Serial serum cryptococcal antigen titers every 1–3 months; renal function (BUN, CREA) monitoring if using amphotericin B; CBC monitoring if using 5-FC [1].

The overall prognosis for feline cryptococcosis is favorable when diagnosed early and treated with sustained antifungal therapy [1]. Key prognostic data from the available literature:

• ·In the retrospective evaluation by Gerds-Grogan and Dayrell-Hart (1997), a cohort of 19 cats showed notable neurological and ophthalmological involvement, which are recognized negative prognostic indicators [3].
• ·Cases limited to the nasal cavity and skin generally carry the best prognosis, with many cats achieving clinical cure [1][6].
• ·CNS involvement significantly worsens prognosis; neurological signs may improve slowly or incompletely even with appropriate therapy, and fatality rates are higher in this subset [1][3].
• ·Uncontrolled concurrent immunosuppressive disease (e.g., advanced FeLV infection) is associated with poorer outcomes [1].
• ·Antigen titer is the most reliable prognostic marker: a consistently declining titer with treatment indicates favorable response, whereas a rising or persistently high titer is associated with treatment failure and higher mortality [1].
• ·Early reports suggest that the majority of cats with nasal/cutaneous disease respond to azole monotherapy, while cats requiring amphotericin B-based induction (reflecting more severe disease) have guarded to fair prognosis [1][5].

Note: Large-scale prospective survival statistics (e.g., specific percentage survival rates at defined time points) are not available in the cited references for feline cryptococcosis. The literature consistently characterizes overall prognosis as favorable with appropriate management, but precise numerical survival rates await larger prospective studies.

Environmental Management

• ·Minimizing cats' contact with heavily contaminated substrates (soil enriched with pigeon or other bird droppings, decaying organic matter associated with C. gattii tree species) is the most practical preventive measure [1][6].
• ·Keeping cats indoors reduces, but does not eliminate, exposure risk, as airborne spores can enter indoor environments [5].
• ·Owners should avoid allowing cats to roam in areas with known heavy environmental fungal burden (e.g., pigeon roost sites, accumulated bird feces) [1][6].

Immunological Considerations

• ·Cats with underlying immunosuppressive conditions (FIV, FeLV, long-term corticosteroid treatment) should be considered at elevated risk; minimizing unnecessary immunosuppression and controlling viral retroviral disease may reduce susceptibility [1].
• ·No licensed vaccine against Cryptococcus is currently available for cats [1][5].

Zoonotic and Public Health Context

• ·Direct cat-to-human transmission has not been documented; the shared risk is environmental [1][6].
• ·Immunocompromised owners (e.g., HIV-positive individuals, transplant recipients) should be counseled about shared environmental exposure risks when a household cat is diagnosed [1][6].
• ·Routine hygiene measures (handwashing after handling infected animals or their secretions) are prudent precautions [6].

No Prophylactic Antifungal Regimen is currently recommended for healthy cats in endemic areas; prophylaxis may be considered on a case-by-case basis for severely immunocompromised cats in high-exposure environments, at the clinician's discretion [1][5].